Valiente, ManuelOrtega-Paino, Eva2024-11-182024-11-182024-01Trends Cancer . 2024 Jan;10(1):1-4.https://hdl.handle.net/20.500.12105/25524We thank all members of the Brain Metastasis Group, the CNIO Biobank, and RENACER for their contributions to create and develop this initiative. We want to thank GEPAC for their support and CNIO Core Facilities for their excellent assistance. We are especially grateful to patients who donated their samples. RENACER and all associated studies have been developed thanks to funding received from Fundacion Ramon Areces [CIVP20S10662 (E.O.P.) and CIVP19S8163 (M.V.) ] ; ISCIII (PT20/00070) (E.O.P.) ; Worldwide Cancer Research (19-0177) (M.V.) ; H2020-FETOPEN-2018-2019-2020-01 (828972) (M.V.) ; AECC (LABAE19002VALI) (M.V.) ; ERC CoG (864759) (M.V.) ; The Mark Foundation (21-05-ASP) (M.V.) ; MICINN/AEI/10.13039/501100011033 by the European Regional Development Fund (ERDF-EU) (PID2021-124582OB-I00) (M.V.) ; ERANET-TRANSCAN-3 (TRANSCAN2021-2023) (M.V.) with funds from Instituto de Salud Carlos III/NextGenerationEU/PRTR (AC20/00114) and FC AECC (TRNSC213878VALI) ; and AstraZeneca (10049582/5522) (M.V.) .Multidisciplinary patient-centered networks offer access to difficult-to-get samples and initiate projects from human material. Improving such networks to include 'living' samples could be transformative, not only for research but for clinical trial design, especially when focused on unmet clinical needs, such as brain metastasis.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/biobankdrug-screeningnetworkomicspatient-derived organotypic culture (PDOC)personalized medicineAttribution-NonCommercial-NoDerivatives 4.0 International378027391011-4Trends in Canceropen access